A Phase 3 interventional study of Standard Care and intravitreal triamcinolone injection in Macular Edema, Cystoid and Retinal Vein Occlusion, sponsored by The Emmes Company, LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-02.
Sponsored by The Emmes Company, LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing triamcinolone in Macular Edema — 1 open to participants now, 1 under way, none of them phase 3. Triamcinolone · Macular Edema.
Among the 38 studies testing triamcinolone in Macular Edema, this one is the 3rd largest by enrollment of the 35 interventional ones that give a count, is the only one that started in 2004, is one of 15 in phase 3, and was the 3rd registered.
758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →1 of the 38 studies testing triamcinolone in Macular Edema is open now, in 1 country. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Healthy volunteers
By country, each count listing its studies:
Triamcinolone: first FDA approval 1957 (ARISTOCORT). What it is approved for, and how studies give it, is on its page →
Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 17 · Phase 4 4
First in 2002; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 682 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 71 across the 35 interventional studies. Of the 32 that completed or were terminated, 7 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 38 have an industry lead sponsor. The 10 most frequent:
The Emmes Company, LLC is the lead sponsor of 11 studies on the registry; none are open to participants now.
The Emmes Company, LLC has 1 study filed under Macular Edema — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 38 studies testing triamcinolone in Macular Edema, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The SCORE Study will compare the effectiveness and safety of standard care to intravitreal injection(s) of triamcinolone for treating macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).
Macular edema is a major cause of vision loss in patients with CRVO and BRVO. Both CRVO and BRVO are common retinal problems and are caused by a blockage in one of the large retinal veins (central retinal vein occlusion - CRVO) or smaller retinal veins (branch retinal vein occlusion - BRVO). Currently, there is no effective treatment for macular edema associated with CRVO and standard care treatment is observation. Grid laser photocoagulation may be effective for some patients for macular edema associated with BRVO, but many patients derive limited benefit from this treatment. Therefore, the development of new treatment modalities for macular edema caused by these two conditions is an important research goal.
Over the last several years, many patients with macular edema from CRVO and BRVO have been treated with an injection of a type of steroid called triamcinolone directly into the eye. This type of injection is called an intravitreal injection. The triamcinolone preparation commonly injected into the eye is Kenalog and is FDA-approved only for use in muscles and joints. The SCORE Study will use a formulation of triamcinolone made specifically for the eye.
The SCORE Study is a multicenter, randomized, Phase III trial to compare the effectiveness and safety of standard care versus triamcinolone injection(s) for the treatment of macular edema associated with CRVO and BRVO. In each of the two disease areas, 630 participants will be randomized (similar to a flip of a coin) in a 1:1:1 ratio to one of three groups: standard care, intravitreal triamcinolone 4 mg, or intravitreal triamcinolone 1 mg. After randomization, participants will be examined every 4 months through 3 years to collect ophthalmic information, including visual acuity, intraocular pressure, optical coherence tomography, and fundus photography . Fluorescein angiography will be performed at 4, 12 and 24 months. Repeat intravitreal injections of triamcinolone and repeat laser treatment will be provided as clinically indicated based on protocol-specific guidelines.
The primary outcome is improvement by 15 or more letters from baseline in best-corrected ETDRS visual acuity score at the 12-month visit. Secondary outcomes include changes from baseline in best-corrected ETDRS visual acuity score, changes in retinal thickness as assessed by stereoscopic color fundus photography and optical coherence tomography, and adverse ocular outcomes.
Inclusion Criteria:
Exclusion Criteria: refer to SCORE Study website at https://web.emmes.com/study/score/ for listing.
Other: Standard Care
Drug: intravitreal triamcinolone injection
Drug: intravitreal triamcinolone injection
Other: Standard Care
Drug: intravitreal triamcinolone injection
Drug: intravitreal triamcinolone injection
CRVO: observation; BRVO: standard care
1 mg dose
4 mg
The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit
Visual acuity testing was done using electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity testing at 3 meters using the Electronic Visual Acuity Tester by a SCORE certified technician. A masked visual acuity examiner with no knowledge of treatment assignments performed visual acuity testing at the 4-month, 12-month, 24-month and 36-month visits. An E-ETDRS visual acuity score of 85 is approximately 20/20, and a score of 20 letters is approximately 20/400. A visual acuity letter score change of 15 is about three lines on a vision chart.
Time frame: Change from baseline to 12 months
Changes From Baseline in Best-corrected ETDRS Visual Acuity Score
Time frame: 12 months
Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography
Time frame: 12 months
Adverse Ocular Outcomes
Time frame: 12 months
Between November 8, 2004, and February 29, 2008, 271 patients with central retinal vein occlusion (CRVO) were enrolled from 66 clinical sites and 411 patients with branch retinal vein occlusion (BRVO) were enrolled from 75 clinical sites across the United States. Participant flow data are reported for the primary outcome measure (12 months).
| Milestone | CRVO Observation | CRVO 1 mg Dose Triamcinolone Acetonide | CRVO 4 mg Dose Triamcinolone Acetonide | BRVO Standard Care | BRVO 1 mg Dose Triamcinolone Acetonide | BRVO 4 mg Dose Triamcinolone Acetonide |
|---|---|---|---|---|---|---|
| Started | 88 | 92 | 91 | 137 | 136 | 138 |
| Completed | 73 | 83 | 82 | 121 | 121 | 125 |
| Not completed | 15 | 9 | 9 | 16 | 15 | 13 |
Visual acuity testing was done using electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity testing at 3 meters using the Electronic Visual Acuity Tester by a SCORE certified technician. A masked visual acuity examiner with no knowledge of treatment assignments performed visual acuity testing at the 4-month, 12-month, 24-month and 36-month visits. An E-ETDRS visual acuity score of 85 is approximately 20/20, and a score of 20 letters is approximately 20/400. A visual acuity letter score change of 15 is about three lines on a vision chart.
| Participants | CRVO Observation | CRVO 1 mg Dose Triamcinolone Acetonide | CRVO 4 mg Dose Triamcinolone Acetonide | BRVO Standard Care | BRVO 1 mg Dose Triamcinolone Acetonide | BRVO 4 mg Dose Triamcinolone Acetonide |
|---|---|---|---|---|---|---|
| The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit | 5 | 22 (-6.4 to 4.1) | 21 (-6.3 to 4.0) | 35 (1.1 to 7.3) | 31 (2.8 to 8.6) | 34 (0.9 to 7.2) |
| letters read | CRVO Observation | CRVO 1 mg Dose Triamcinolone Acetonide | CRVO 4 mg Dose Triamcinolone Acetonide | BRVO Standard Care | BRVO 1 mg Dose Triamcinolone Acetonide | BRVO 4 mg Dose Triamcinolone Acetonide |
|---|---|---|---|---|---|---|
| Changes From Baseline in Best-corrected ETDRS Visual Acuity Score | -12.1 (-17.1 to -7.1) | -1.2 (-6.4 to 4.1) | -1.2 (-6.3 to 4.0) | 4.2 (1.1 to 7.3) | 5.7 (2.8 to 8.6) | 4.0 (0.9 to 7.2) |
| um | CRVO Observation | CRVO 1 mg Dose Triamcinolone Acetonide | CRVO 4 mg Dose Triamcinolone Acetonide | BRVO Standard Care | BRVO 1 mg Dose Triamcinolone Acetonide | BRVO 4 mg Dose Triamcinolone Acetonide |
|---|---|---|---|---|---|---|
| Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography | -277 (-418 to -40) | -196 (-390 to -62) | -261 (-407 to -79) | -224 (-411 to -67) | -149 (-279 to -18) | -170 (-304 to -63) |
| events | CRVO Observation | CRVO 1 mg Dose Triamcinolone Acetonide | CRVO 4 mg Dose Triamcinolone Acetonide | BRVO Standard Care | BRVO 1 mg Dose Triamcinolone Acetonide | BRVO 4 mg Dose Triamcinolone Acetonide |
|---|---|---|---|---|---|---|
| Initiation of IOP-lowering medications | 7 | 18 | 32 | 3 | 11 | 57 |
| IOP > 35 mm HG | 1 | 5 | 8 | 1 | 2 | 14 |
| IOP > 10 mm HG above baseline | 2 | 15 | 24 | 1 | 12 | 50 |
| Laser peripheral iridotomy | 0 | 0 | 1 | 0 | 0 | 1 |
| Trabeculectomy | 0 | 0 | 0 | 0 | 0 | 0 |
| Tube shunt | 0 | 2 | 0 | 0 | 0 | 0 |
| Cataract: lens opacity onset or progression | 12 | 20 | 25 | 15 | 27 | 38 |
| Cataract surgery | 0 | 0 | 4 | 3 | 0 | 4 |
| Infectious endophthalmitis | 0 | 0 | 0 | 0 | 0 | 1 |
| Noninfectious endophthalmitis | 0 | 0 | 0 | 0 | 0 | 0 |
| Retinal detachment | 0 | 0 | 0 | 1 | 1 | 0 |
| Iris neovascularization | 2 | 9 | 4 | 1 | 1 | 2 |
| Retinal neovascularization | 4 | 2 | 2 | 5 | 1 | 3 |
| Vitreous hemorrhage | 4 | 4 | 0 | 2 | 1 | 3 |
| YAG capsulotomy | 1 | 0 | 0 | 1 | 0 | 1 |
| Sector or panretinal photocagulation | 5 | 9 | 3 | 5 | 1 | 4 |
| Pars plana vitrectomy | 1 | 2 | 0 | 1 | 0 | 1 |
Collected over Three years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CRVO Observation | 0/88 (0%) | 32/88 (36.4%) | 76/88 (86.4%) |
| CRVO 1 mg Dose Triamcinolone Acetonide | 1/92 (1.1%) | 37/92 (40.2%) | 87/92 (94.6%) |
| CRVO 4 mg Dose Triamcinolone Acetonide | 2/91 (2.2%) | 53/91 (58.2%) | 89/91 (97.8%) |
| BRVO Standard Care | 3/137 (2.2%) | 47/137 (34.3%) | 118/137 (86.1%) |
| BRVO 1 mg Dose Triamcinolone Acetonide | 2/136 (1.5%) | 49/136 (36%) | 132/136 (97.1%) |
| BRVO 4 mg Dose Triamcinolone Acetonide | 2/138 (1.4%) | 79/138 (57.2%) | 133/138 (96.4%) |
| Event | CRVO Observation | CRVO 1 mg Dose Triamcinolone Acetonide | CRVO 4 mg Dose Triamcinolone Acetonide | BRVO Standard Care | BRVO 1 mg Dose Triamcinolone Acetonide | BRVO 4 mg Dose Triamcinolone Acetonide |
|---|---|---|---|---|---|---|
| CataractEye disorders | 5/88 | 9/92 | 28/91 | 12/137 | 16/136 | 40/138 |
| Cataract subcapsularEye disorders | 0/88 | 0/92 | 1/91 | 1/137 | 1/136 | 12/138 |
| GlaucomaEye disorders | 1/88 | 5/92 | 3/91 | 0/137 | 0/136 | 2/138 |
| Cerebrovascular accidentNervous system disorders | 2/88 | 0/92 | 4/91 | 3/137 | 1/136 | 3/138 |
| Angina unstableCardiac disorders | 3/88 | 0/92 | 0/91 | 0/137 | 0/136 | 0/138 |
| Intraocular pressure increasedInvestigations | 3/88 | 2/92 | 3/91 | 0/137 | 0/136 | 4/138 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/88 | 0/92 | 3/91 | 0/137 | 0/136 | 0/138 |
| SyncopeNervous system disorders | 0/88 | 0/92 | 3/91 | 1/137 | 1/136 | 0/138 |
| PneumoniaInfections and infestations | 2/88 | 2/92 | 0/91 | 1/137 | 4/136 | 2/138 |
| CellulitisInfections and infestations | 2/88 | 0/92 | 0/91 | 0/137 | 2/136 | 1/138 |
| Event | CRVO Observation | CRVO 1 mg Dose Triamcinolone Acetonide | CRVO 4 mg Dose Triamcinolone Acetonide | BRVO Standard Care | BRVO 1 mg Dose Triamcinolone Acetonide | BRVO 4 mg Dose Triamcinolone Acetonide |
|---|---|---|---|---|---|---|
| Foreign body in eyeInjury, poisoning and procedural complications | 5/88 | 31/92 | 22/91 | 4/137 | 67/136 | 31/138 |
| Intraocular pressure increasedInvestigations | 8/88 | 20/92 | 42/91 | 7/137 | 19/136 | 64/138 |
| MyodesopsiaEye disorders | 8/88 | 32/92 | 34/91 | 17/137 | 59/136 | 45/138 |
| Conjunctival haemorrhageEye disorders | 3/88 | 34/92 | 30/91 | 9/137 | 54/136 | 54/138 |
| Eye painEye disorders | 6/88 | 15/92 | 18/91 | 9/137 | 23/136 | 18/138 |
| Vitreous detachmentEye disorders | 8/88 | 16/92 | 10/91 | 15/137 | 21/136 | 12/138 |
| CataractEye disorders | 10/88 | 9/92 | 14/91 | 15/137 | 19/136 | 21/138 |
| Cataract subcapsularEye disorders | 3/88 | 8/92 | 12/91 | 2/137 | 13/136 | 16/138 |
| Visual acuity reducedEye disorders | 10/88 | 12/92 | 10/91 | 6/137 | 11/136 | 13/138 |
| Eye irritationEye disorders | 2/88 | 11/92 | 9/91 | 6/137 | 17/136 | 8/138 |
| Age, Categorical(Participants) | CRVO Observation | CRVO 1 mg Dose Triamcinolone Acetonide | CRVO 4 mg Dose Triamcinolone Acetonide | BRVO Standard Care | BRVO 1 mg Dose Triamcinolone Acetonide | BRVO 4 mg Dose Triamcinolone Acetonide | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 25 | 35 | 34 | 62 | 54 | 55 | 265 |
| >=65 years | 63 | 57 | 57 | 75 | 82 | 83 | 417 |
| Age, Continuous(years) | CRVO Observation | CRVO 1 mg Dose Triamcinolone Acetonide | CRVO 4 mg Dose Triamcinolone Acetonide | BRVO Standard Care | BRVO 1 mg Dose Triamcinolone Acetonide | BRVO 4 mg Dose Triamcinolone Acetonide | Total |
|---|---|---|---|---|---|---|---|
| Mean | 69.2 ± 12.8 | 67.4 ± 12.4 | 67.5 ± 12.0 | 66.9 ± 11.5 | 67.2 ± 11.5 | 68.1 ± 10.6 | 67.7 ± 11.2 |
| Sex: Female, Male(Participants) | CRVO Observation | CRVO 1 mg Dose Triamcinolone Acetonide | CRVO 4 mg Dose Triamcinolone Acetonide | BRVO Standard Care | BRVO 1 mg Dose Triamcinolone Acetonide | BRVO 4 mg Dose Triamcinolone Acetonide | Total |
|---|---|---|---|---|---|---|---|
| Female | 40 | 43 | 40 | 71 | 68 | 63 | 325 |
| Male | 48 | 49 | 51 | 66 | 68 | 75 | 357 |
| Region of Enrollment(participants) | CRVO Observation | CRVO 1 mg Dose Triamcinolone Acetonide | CRVO 4 mg Dose Triamcinolone Acetonide | BRVO Standard Care | BRVO 1 mg Dose Triamcinolone Acetonide | BRVO 4 mg Dose Triamcinolone Acetonide | Total |
|---|---|---|---|---|---|---|---|
| United States | 88 | 92 | 91 | 137 | 136 | 138 | 682 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data sets will be provided to qualified investigators under a Data Use Agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: to be set forth in data use agreement
Access criteria: qualified investigators
The record gives a start of Oct 2004, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triamcinolone
The Emmes Company, LLC